ontario regulation 645/05
made under the
Ontario drug benefit act
Made: December 7, 2005
Filed: December 9, 2005
Published on e-Laws: December 12, 2005
Printed in The Ontario Gazette: December 24, 2005
Amending O. Reg. 201/96
(General)
1. (1) The definition of “Formulary” in subsection 1 (1) of Ontario Regulation 201/96 is revoked and the following substituted:
“Formulary” means the Ministry of Health and Long-Term Care publication titled “Drug Benefit Formulary/Comparative Drug Index” (No. 39) dated September 27, 2005, and includes the following amendments to the publication,
1. Amendments dated January 12, 2006;
(2) Section 1 of the Regulation is amended by adding the following subsection:
(1.1) For the purposes of this Regulation, items 17 and 18 of Part III of the Formulary shall be read as follows:
VORICONAZOLE
17 |
50mg Tab |
|
|
11.8800 |
|
02256460 |
Vfend |
PFI |
11.8800 |
18 |
200mg Tab |
|
|
47.5000 |
|
02256479 |
Vfend |
PFI |
47.5000 |
|
Reason for Use Code |
Clinical Criteria |
||
|
399 |
Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole. The first prescription must be written by a physician based at the hospital where the patient was hospitalized. Note: Limited to 3 months of reimbursement. LU Authorization Period: 1 year. |
2. Clause 12 (1) (b) of the Regulation is amended by striking out “Canadian Coordinating Office of Health Technology Assessment” wherever it appears and substituting in each case “Canadian Coordinating Office for Health Technology Assessment.”
3. This Regulation comes into force on January 12, 2006.